Why Helus Pharma Inc.’s (HELP) Stock Is Up 6.53%
As of Monday, October 26, Helus Pharma Inc.’s HELP share price has surged by 6.53%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’s preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
Commentary & Analysis
Why Helus Pharma Inc.’s (HELP) Stock Is Up 5.62%
As of Wednesday, October 21, Helus Pharma Inc.’s HELP share price has surged by 5.62%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Helus Pharma Inc.’s (HELP) Stock Is Up 5.89%
As of Tuesday, October 20, Helus Pharma Inc.’s HELP share price has surged by 5.89%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Helus Pharma Inc.’s (HELP) Stock Is Up 7.95%
As of Tuesday, October 20, Helus Pharma Inc.’s HELP share price has surged by 7.95%, which has investors questioning if this is right time to sell.Michael Rose
Why Helus Pharma Inc.’s (HELP) Stock Is Up 6.74%
As of Tuesday, October 20, Helus Pharma Inc.’s HELP share price has surged by 6.74%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | HELP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $797.1 | $498.4 | 43% |
|
| Shares Out (Mil) | 52.3 | 42.8 | 49% |
|
| Institutional Ownership | 72.0% | 81.2% | 44% |
|
| Float (Mil) | 58.1 | 44.5 | 50% |
|
| Beta | 0.63 | 0.72 | 36% |
|
| Avg Daily Volume (000s) | 1,416 | 264 | 76% |
|
| Price Change (52-week) |
67.6% | 56.1% | 90% |
|
| Growth | HELP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (42.0%) | (2.0%) | 9% |
|
| EPS (5yr) | 15.3% | 15.0% | 58 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (40.2%) | (15.1%) | 11% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 5 | 2 | |
| Current EPS | ($0.720) | ($2.924) | ($1.759) | |
| Month Ago EPS | ($0.676) | ($2.652) | ($1.810) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.687) | ($2.909) | ($1.971) | |
| Year/Year Chg | (21.2%) | (31.2%) | (83.7%) | |
| Financials | HELP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($171) | ($11) | 8% |
|
| EPS (TTM) | ($4.049) | ($0.700) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($141) | ($7) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $48 | $3 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $739 | $493 | 38% |
|
| Valuation | HELP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.79 | 2.16 | 65% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | HELP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.3% | na |
|
| ROA | (72.8%) | (21.8%) | 8% |
|
| ROE | (86.9%) | (20.2%) | 10% |
|
| Liabilities to Assets | 6.8% | 32.0% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Helus Pharma Inc. did not pass any screens on 10/28/2026.
